Indications for: Methazolamide
Ocular conditions where lowering intraocular pressure would be of therapeutic benefit (eg, chronic open-angle glaucoma, secondary glaucoma, pre-op in acute angle-closure glaucoma).
50–100mg 2–3 times daily.
Hypokalemia. Hyponatremia. Severe renal, hepatic, or adrenocortical impairment. Hyperchloremic acidosis. Cirrhosis. Long-term use in angle-closure glaucoma.
Sulfonamide allergy. Respiratory impairment (eg, pulmonary obstruction or emphysema). Do baseline CBC and platelet counts before starting and during therapy. Monitor serum electrolytes periodically. Pregnancy (Cat.C). Nursing mothers: not recommended.
Carbonic anhydrase inhibitor.
May inhibit renal excretion of basic drugs and promote excretion of acidic drugs. Caution with high-dose aspirin; may increase salicylate toxicity. Caution with corticosteroids; may develop hypokalemia.
Paresthesias, tinnitus, fatigue, malaise, anorexia, GI upset, dysguesia, drowsiness, confusion, metabolic acidosis, electrolyte imbalance, transient myopia; hepatic insufficiency, blood dyscrasias, anaphylaxis, urticaria, melena, hematuria, glycosuria, flaccid paralysis, photosensitivity, convulsions; rare: crystalluria, renal calculi.
Formerly known under the brand name Neptazane.
Renal. Half-life: ~14 hours.